DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: COPAXONE, GLATOPA (glatiramer acetate)
*****************************************************
#Post#: 2432--------------------------------------------------
Long-acting glatiramer acetate (GA Depot) for RRMS and PPMS anno
unced
By: agate Date: March 9, 2019, 1:39 am
---------------------------------------------------------
This new MS drug, to be marketed for RRMS and PPMS, seems to be
a "depot" version of glatiramer acetate (Copaxone), injected
every 4 weeks. Just when it will become available isn't clear:
HTML http://www.globenewswire.com/news-release/2019/02/21/1739488/0/en/Mapi-Pharma-to-Host-Key-Opinion-Leader-Meeting-on-Long-Acting-Glatiramer-Acetate-GA-Depot-for-Primary-Progressive-Multiple-Sclerosis-and-New-Treatments-for-MS.html
#Post#: 2445--------------------------------------------------
Re: Long-acting glatiramer acetate (GA Depot) for RRMS and PPMS
announced
By: ewizabeth Date: March 25, 2019, 11:10 am
---------------------------------------------------------
I bet that will be expensive compared to the injections.
#Post#: 2447--------------------------------------------------
Re: Long-acting glatiramer acetate (GA Depot) for RRMS and PPMS
announced
By: agate Date: March 25, 2019, 11:26 am
---------------------------------------------------------
The drug companies usually seem to charge whatever price the
market will bear--and the sky may be the limit.
#Post#: 3693--------------------------------------------------
Use of GA depot for progressive MS given US patent
By: agate Date: June 24, 2022, 1:11 am
---------------------------------------------------------
The injection, given every 4 weeks, is intramuscular. The main
justification for bringing this new type of glatiramer acetate
onto the market seems to be that it would be more convenient for
people, and so patient compliance would be improved.
From Multiple Sclerosis News Today (April 2, 2022)--"Use of GA
Depot in Treating Progressive MS Given US Patent":
HTML https://multiplesclerosisnewstoday.com/news-posts/2022/04/1/ga-depot-mapi-pharma-given-us-patent-treatment-progressive-ms/
#Post#: 4346--------------------------------------------------
US FDA declines to approve GA Depot (yet)
By: agate Date: March 12, 2024, 1:58 pm
---------------------------------------------------------
The US FDA has declined to approve GA Depot. Apparently more
information is needed, and this may be just a matter of a delay.
From Neurology Live (March 22, 2024)--"FDA Issues Complete
Response Letter for Long-Acting Form of Glatiramer Acetate for
Relapsing Multiple Sclerosis":
HTML https://bit.ly/48QUXIA
*****************************************************